Poxel SA and Sumitomo Pharma: A Closer Look at TWYMEEG®’s Sales Performance and Strategic Growth Initiatives In the rapidly evolving landscape of metabolic disease treatments, Poxel SA (Euronext: POXEL –…
Ethris Reports Promising Phase 1 Data for mRNA Candidate ETH47 in Asthma Ethris GmbH, a pioneering biotechnology company specializing in next-generation RNA therapeutics and vaccines, has unveiled encouraging topline data…
Owkin Announces First Patient Dosed in Phase I Trial of OKN4395 for Solid Tumors Owkin, a leader in AI-driven biotech, has reached a significant milestone in its innovative journey with…
Galderma Leads in Aesthetic Injectables & Weight Loss Research New research reveals that loose or sagging skin on the face and neck is most commonly observed after medication-driven weight loss,…
40 Years of Excellence in Laser Technology Quanta System proudly celebrates a major milestone in 2025-40 years of pioneering innovation in laser technology. Since its founding in 1985, it has…
KORU Medical Systems Partners on Phase III Trial for Rare Renal Disorder Treatment, Expanding Its Reach in Subcutaneous Infusion Solutions KORU Medical Systems (NASDAQ: KRMD), a leading innovator in large-volume…
Enveric Biosciences Secures Patent Protection for Breakthrough Neuroplastogen EB-003 In a significant milestone for its innovative drug development pipeline, Enveric Biosciences (NASDAQ: ENVB) has announced the receipt of a Notice…
Ferrer Achieves Compliance Leader Verification™: A Testament to Excellence in Ethics and Corporate Responsibility In a significant milestone for ethical business practices, Ferrer, a global pharmaceutical company headquartered in Barcelona,…
RevBio Secures 10th Patent for TETRANITE®: Expanding Protection for Revolutionary Bone Adhesive Technology In a significant milestone for regenerative medicine, ITS, a clinical-stage medical device company, has been granted its…
Lead Capital Partners and Petra Capital Partners Propel Lieberman’s Growth with Strategic Platform Investment In a landmark move set to bolster its position as a leader in primary market research,…
Owkin Achieves Milestone with First Patient Dosed in AI-Optimized Phase I Trial of OKN4395, a First-in-Class Triple Inhibitor for Solid Tumors On January 22, 2025, Owkin, the pioneering end-to-end AI…
Biologics Market 2024-2030: Global Industry Poised to Reach $732.4 Billion – Trends, Drivers, and Key Insights The global biologics market is experiencing unprecedented growth, with its value estimated at $421.1…